Trial Profile
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Fixed-Dose Study Evaluating the Effect of One Dose of Rimonabant (20 mg/Day) on Glycemic Control in Type 2 Diabetic Patients Inadequately Controlled With Insulin.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Rimonabant (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms ARPEGGIO
- Sponsors Sanofi
- 08 Sep 2008 This study was presented at the 44th Annual Meeting of the European Association for the Study of Diabetes.
- 10 Jun 2008 Primary endpoint 'Proportion of glycosylated haemoglobin' has been met.
- 12 Feb 2008 According to a media release by sanofi-aventis, results will be presented at the 68th Annual Scientific Sessions of the American Diabetes Association, held in San Francisco, California, USA from 6-10 June 2008.